Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Study of Faricimab in Neovascular Age-related Macular Degeneration
KCT0011597Phase 4Recruiting
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in exudative macular degeneration, sponsored by Roche. Started Jun 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on KCT0011597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011597.